| Quality assessment | No of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Treatment | No treatment (diabetes) | Relative (95% CI) | Absolute | ||
| All-cause mortality - 140–159mmHg (follow-up mean 4.4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious1 | none |
230/3355 (6.9%) |
268/2979 (9%) | RR 0.76 (0.64 to 0.9) | 22 fewer per 1000 (from 9 fewer to 32 fewer) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| Stroke - 140–159mmHg (follow-up mean 4.4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious1 | none |
230/3052 (7.5%) |
267/2845 (9.4%) | RR 0.8 (0.68 to 0.95) | 19 fewer per 1000 (from 5 fewer to 30 fewer) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| Heart failure - 140–159mmHg (follow-up mean 4.4 years) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious1 | none |
62/2872 (2.2%) |
76/2757 (2.8%) | RR 0.78 (0.56 to 1.09) | 6 fewer per 1000 (from 12 fewer to 2 more) |
⨁⨁⨁◯ MODERATE | CRITICAL |
Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
From: Evidence review for initiating treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.